Top 50 Medical VC Funds in Ireland

Investor	Medical Ireland investments
Enterprise Ireland	29
Western Development Commission	9
AIB Seed Capital Fund	9
Elkstone Capital Partners	7
HBAN Medtech Syndicate	7
Irrus Investments	7
Act Venture Capital	6
Furthr VC	6
Atlantic Bridge	6
Business Venture Partners	5
SOSV	5
Fountain Healthcare Partners	5
Kernel Capital	5
Seroba Life Sciences	4
NDRC	4
Medtech Syndicate Nominee	3
Enterprise Equity	3
Oyster Capital Partners	2
EIT Health	2
Life Sciences Fund Amsterdam	2
Ascentifi	2
Glanzmann Enterprises	2
Delta Partners	2
Cantor Fitzgerald	2
SVG Ventures	2
SVG Ventures	2
Partisan Management Group	2
Boole	2
New Leaf Venture Partners	1
Malin Corporation	1
Norgine Ventures	1
Earlybird Venture Capital	1
European Investment Bank	1
Manatt Venture Fund	1
Crow Rock Capital	1
Sofinnova Investments	1
Medicxi	1
Apicap	1
HBM-MedFocus	1
Moffett Investment Holdings	1
Frazier Healthcare Partners	1
DHKN	1
HealthCap	1
Keiretsu Forum Northwest	1
Kreos Capital	1
EarlyBird	1
Foresight Group	1
Inventages Venture Capital Investment Inc.	1
Silicon Valley Bank	1
Canaan Partners	1

Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.

Investment focus

Software, Health Care, Information Technology
Funding Round, Seed, Series A
Ireland, United States, United Kingdom

Portfolio highlights

Xocean — Using unmanned surface vessels (USVs), XOCEAN offers turnkey data collection services to Surveyors, Companies and Agencies.
Lua Health — We believe the future of well-being is in prevention and early detection. Getting the right help, at the right time.
MarketSizer — MarketSizer offers subscription-based competitive intelligence and market insights for SaaS vendors who want to strategically grow their business.

Supporting communities to grow, investing in businesses to scale and planning for the future of the western region.

Investment focus

Health Care, Medical Device, Biotechnology
Seed, Funding Round, Series A
Ireland, United States

Portfolio highlights

FeelTect — Connected health technology for disruptive improvements to wound care
CitySwift — CitySwift is a data-driven scheduling and planning technology for urban bus networks. It uses artificial intelligence and machine learning to predict journey times and passenger demand, making routes more efficient. Schedulers can create optimized timetables that take into account traffic, events, and hundreds of other external factors, ensuringon-time performance and increased passenger satisfaction.CitySwift was established in 2016 and is operating in Galway, Ireland.
Amara Therapeutics — Amara Therapeutics is passionate about empowering women and men to take control of their pelvic health. Amara Therapeutics use evidence based medicine and behavioural interventions supported by Amara Therapeutics platform of technologies to provide safe, convenient and non-invasive care pathways. At Amara Therapeutics mission is to fix the carepathway for pelvic health patients, connecting healthcare providers, patients and peers through our platform.

The AIB Seed Capital Fund was established in 2007 to provide venture capital for companies at the seed and early stages of development across a range of sectors throughout the Republic of Ireland. The Fund was established under the Enterprise Ireland Seed and Venture Capital Programme 2007-2012.The Fund has a total of â‚¬30m under managementwith AIB and Enterprise Ireland both committing â‚¬15m. It is managed by experienced managers with extensive expertise in making seed and early stage investments, adding value and facilitating business success.The Fund managers are empowered to make seed investments of up to approximately â‚¬500,000. Furthermore, the Fund has the capacity to make investments in later rounds to support the continued growth of investee companies.The Fund will be managed by Enterprise Equity Venture Capital and the Dublin Business Innovation Centre. This unique partnership brings together extensive regional and investment expertise.Enterprise Equity will evaluate and manage all investments outside the city and county of Dublin, as well as investments that require in excess of â‚¬250,000 from the fund within the city and county of Dublin.Dublin Business Innovation Centre (DBIC) will evaluate and manage all investments within the city and county of Dublin when the initial investment amount required from the Fund does not exceed â‚¬250,000.

Investment focus

Software, Health Care, Medical
Seed, Funding Round, Series A
Ireland, United States, Jersey

Portfolio highlights

NewsWhip — The only real-time media monitoring platform that predicts the stories and topics that will matter in the hours ahead.
Offr — Offr is the new way to buy and sell property, quickly and transparently.
Metabolomic Diagnostics — Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy.

Elkstone is an investment firm, focusing on entrepreneurs, senior executives, institutional LPs, the venture community, and the Irish diaspora.The objective of the organization is to boost the economic value and overall well-being of the island of Ireland by expanding a network, facilitating deserving investments, and delivering excellentinvestment performance.

Investment focus

Software, Health Care, Medical
Seed, Funding Round, Series A
Ireland, United Kingdom, United States

Portfolio highlights

Numra — Numra is an artificial intelligence automation for financial operations.
Jamango — Create and play for free in Jamango! Play with our block-based tools to make anything or explore a library of games and worlds instantly. No downloads.
Wellola — Wellola connects clinics & their own clients, anywhere, anytime. It is designed for the forward-thinking healthcare professional. Our cloud-based platform offers secure video-consultation software combined with simple payment/practice management facilities.

HBAN Medtech Syndicate

Investment focus

Medical Device, Medical, Health Care
Seed, Funding Round, Series B
Ireland

Portfolio highlights

FeelTect — Connected health technology for disruptive improvements to wound care
Neurobell — NeuroBell develop novel EEG medical devices for early detection and monitoring of neonatal seizures.
SymPhysis Medical — SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life.About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication oflate-stage cancers, malignant pleural effusion (MPE). MPE causes signiﬁcant shortness of breath and chest pain in up to 15% of patients with cancer.

Irrus Investments is the leading Irish business angel network with international connections. Fueling Irish innovation in medical devices, software, hardware, digital healthcare and life sciences.

Investment focus

Medical Device, Biotechnology, Health Care
Seed, Funding Round, Series A
Ireland, Sweden, United States

Portfolio highlights

FeelTect — Connected health technology for disruptive improvements to wound care
Bluedrop Medical — Evidence shows regular inspection of the feet can greatly reduce the risk of developing a diabetic foot ulcer (DFU).
SymPhysis Medical — SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life.About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication oflate-stage cancers, malignant pleural effusion (MPE). MPE causes signiﬁcant shortness of breath and chest pain in up to 15% of patients with cancer.

Technology-focused, investing capital and expertise to fuel growth in the most promising ideas and companies. Raised c.€600m across multiple funds and invest from seed to growth.We look for companies with potentially cutting-edge, category-defining businesses in markets including application software, IT infrastructure, communications, Internetand mobile. We help founders create and scale businesses globally. We work as a small team with diverse strengths accessing a community of over 200 founders. The teams and companies we back scale their investor base as they scale their business execution and ambition. We work closely with them in this process. Over the past 25 years have built a broad network of US and European investors and founders that share our vision and approach.Act is based in Dublin, Ireland.Our most recent funds are supported by the European Investment Fund.

Investment focus

Software, Information Technology, SaaS
Funding Round, Seed, Series A
Ireland, United States, United Kingdom

Portfolio highlights

GridBeyond — Endeco's Energy ManagementSystem (EMS) provides wirelessenergy management and controlsystems for retail, commercial andindustrial users. Applications includebuilding control, refrigeration control,demand management, priceresponse, energy efficiency, anddemand response. Our automatedwireless systems seamlesslyintegrate intoyour existingoperations and/or BuildingManagement System (BMS) withoutany training of retail staff required.
CitySwift — CitySwift is a data-driven scheduling and planning technology for urban bus networks. It uses artificial intelligence and machine learning to predict journey times and passenger demand, making routes more efficient. Schedulers can create optimized timetables that take into account traffic, events, and hundreds of other external factors, ensuringon-time performance and increased passenger satisfaction.CitySwift was established in 2016 and is operating in Galway, Ireland.
Mavarick AI — Mavarick helps manufacturers to achieve sustainability breakthroughs with AI-Driven Carbon Reporting & Management across their operations & entire supply chain

Furthr VC invests in transformative tech. Furthr Venture Capital invests in scalable, early-stage companies. We help Ireland's next generation of technology.

Investment focus

Medical, Medical Device, Health Care
Seed, Funding Round, Pre-Seed
Ireland

Portfolio highlights

GREYSCOUT — Need brand protection? Our best brand protection software monitors & removes unauthorized listings, helping businesses fight online counterfeiting.
Neurobell — NeuroBell develop novel EEG medical devices for early detection and monitoring of neonatal seizures.
SymPhysis Medical — SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life.About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication oflate-stage cancers, malignant pleural effusion (MPE). MPE causes signiﬁcant shortness of breath and chest pain in up to 15% of patients with cancer.

Atlantic Bridge is a Growth Equity Firm with a Cross Border Value Add strategy. We invest in deep technology companies in Europe and the US. Our team is made up of successful entrepreneurs and senior technology industry executives and we invest in strong ambitious entrepreneurs and management teams that have the passion and drive to scale up andexploit major growth opportunities. We help our portfolio companies expand and grow internationally through our global platform with our team and offices in London, Dublin, Munich, Paris and Palo Alto.Atlantic Bridge brings together a unique team of technology entrepreneurs, experienced managers, finance professionals, and investment experts. The team contains a wealth of international business experience across Europe, the UK and the US. They have worked together in various capacities for the last 30 years, bringing a true partnership approach to their firm and their investments. Its investors include the founders, leading institutional investors, and private investors with a track record of investment in successful technology companies.Atlantic Bridge has developed a unique and differentiated strategy that focuses on specific technology themes and the implementation of the “Atlantic Bridge Model” for scaling companies internationally. The “Bridge Model” accelerates the scale-up of technology companies in Europe and the US. This approach is highly differentiated and has delivered strong performance results to date.

Investment focus

Software, Information Technology, Artificial Intelligence
Series A, Series B, Funding Round
United States, Ireland, United Kingdom

Portfolio highlights

Neurobell — NeuroBell develop novel EEG medical devices for early detection and monitoring of neonatal seizures.
Vertigenius — Vertigenius designs and deploys customized exercises using an easy-to-use clinician portal and even uses a Vertigenius head sensor to consult and manage patients with dizziness and imbalance.
Cambridge Mechatronics — Cambridge Mechatronics (CML) is a high technology design and engineering company based in Cambridge, UK. We specialise in pioneering and developing cutting-edge mechatronic platform technology from concept to mass production. We achieve this through technology licensing or partnerships with global manufacturing corporations. Our intellectualproperty portfolio consists of over 100 granted patents that we can exploit.

Business Venture Partners was founded in 2004 as a corporate finance adviser for SME/owner managed businesses. The investment team is comprised of Elliott Griffin, Ronan Smith, Edel Coen and Mark Ruane and the team skills combine deep industry knowledge with experience in venture investing, corporate finance and international expansion. Theteam works on behalf of its clients buying and selling companies, raising finances, working with start-ups and advising on strategic growth, business succession and owner exits.Since 2007, BVP has successfully raised and managed 10 Simple Green BES and EII Funds. They have invested, on behalf of their investors, in some of Ireland’s most innovative companies such as Celtic Bioenergy, EFT Controls, and UrbanVolt. Our investment strategy is to spread investments over project finance and a portfolio of high potential companies. Their philosophy is to work hard with each investment to deliver valuable support for the company promoters and build shareholder value for their investors.In 2016 BVP launched The 10th BVP Green EII Fund. The fund provides eligible investors with the opportunity to avail of up to 40% income tax relief and provides the investor access to a portfolio of cleantech companies and renewable energy projects. The 11th Green Fund will be launched in Q4 2017.

Investment focus

Health Care, Information Technology, Medical
Seed, Funding Round, Series A
Ireland, Luxembourg, The Netherlands

Portfolio highlights

OOHPod — Self service parcel lockers for personal and business customers. Choose from a range of plans to suit you. Pay As You Go, Monthly and Premium Subscriptions available. Find your nearest OOHPod parcel locker and start using your out of home flexible address today.
Positive Carbon — Positive Carbon provides an innovative solution for businesses to track, manage, and reduce food waste. With real-time analytics, CO2 calculation, and a comprehensive learning platform, we help you save costs and achieve sustainability goals. Request a demo today to start making a positive environmental impact.
X-BOLT Orthapaedics — X-Bolt Trauma Solutions for osteoporotic bone fixation. FDA 510(k) approved. Clinical studies include the WHITE One (n=100) and WHITE Four (n=1,140) randomized control trials.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

NovoNutrients — NovoNutrients is working to turn waste CO2 into high-value, low-cost proteins and additives for food and feed by developing proprietary microbes and advanced gas fermentation systems.
OncoPrecision — We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity and Resistance Test, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access toPrecision Oncology and improve cancer patients' lives.
Sodex Innovations — Sodex Innovations is a company which is specialized in developing assistance-systems and automating-kits for excavators

Fountain Healthcare Partners is an Irish based life science venture capital fund. Fountain is exclusively focused on the life science sector. Specific areas of interest to them are: specialty pharma, medical devices, biotechnology and diagnostics. They will deploy the majority of their capital in Europe with a strong focus on Ireland.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Series C
Ireland, United States, France

Portfolio highlights

MMI — The future of Microsurgery: microinstruments that expand the possibilities of surgical interventions. Wristed robotic microinstruments for unprecedented results in microsurgery.
Mainstay Medical — Mainstay Medical is improving quality of life for patients with chronic low back pain through innovative restorative treatment medical device solutions.
Ermium Therapeutics — Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases, based on a breakthrough discovery showing that CXCR4 is a master regulator of inflammation.

Kernel Capital is the independent manager of The Bank of Ireland Kernel Capital Venture Funds, one of the largest and most active sources of equity finance on the island of Ireland. Kernel leverage their extensive network to enable their portfolio companies recruit the highest caliber people, to break into new international markets and to generaterevenues of scale. It is the only investment firm with venture capital Funds dedicated to both jurisdictions on the Island. Kernel have raised over €210M from investors which including their strategic partner Bank of Ireland, Invest NI, Enterprise Ireland, Galway University Foundation, The University of Limerick Foundation, The New York State Common Retirement Fund and undisclosed Family Offices. Consistently delivering strong financial returns for their investors Kernel have led more than 20 substantial trade sales to NASDAQ, NYSE, and LSE listed corporations.

Investment focus

Software, Information Technology, Health Care
Funding Round, Seed, Series A
Ireland, United Kingdom, France

Portfolio highlights

Pretto — Pretto is the only truly transparent online real estate price comparator.Pretto accompanies you until the signing of your loan, free of charge and without commitment.
Pilot Photonics — Welcome to Pilot Photonics, a laser product development company in Dublin, Ireland. We provide optical frequency combs and tunable lasers.
Causeway Sensors — The Affinity, is a compact, bench-top Biosensor providing accurate real-time analysis at an accessible price. The Affinity biosensor and accompanying Access Chip incorporate the latest advancements in Nanotechnology, providing the biochemistry researcher the perfect platform to explore the complex world of biomolecular interactions.

Seroba is a leading European life sciences venture capital firm focused on value creation through backing winning innovations in biotech and medtech.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Funding Round
Ireland, United States, United Kingdom

Portfolio highlights

Shorla Pharma — Shorla Pharma is an Irish specialty pharmaceutical company. It is growing portfolio brings accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical impact.
Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.
Artica Therapeutics — Artica Therapeutics specializes in biotechnological research and development for medical devices, pharmaceutical processes, and food.

NDRC builds high-impact new ventures. By providing the people, time, space and investment needed at the earliest stages of dedicated commercialisation work, NDRC is creating companies worthy of commercial investment and with the ability to scale. The NDRC team has the breadth of knowledge and expertise in technology and markets. NDRC worksside-by-side with researchers, entrepreneurs and venture teams to turn great ideas into successful new ventures.By the end of 2014, NDRC’s portfolio of startup ventures had secured a cumulative €88m in follow-on investment from commercial investors, with a combined market capitalisation of approx. €220m.

Investment focus

Software, Information Technology, E-Commerce
Seed, Pre-Seed, Convertible Note
Ireland, United States, United Kingdom

Portfolio highlights

Nory AI — All of your restaurant operations managed in one platform, powered by AI. Tools that fuel better decision making and fatter profit margins.
Dataships — Dataships uses top level data privacy software to help your brand, no matter your location.
Ceartas DMCA — Ceartas is the leader in piracy protection for creators, brands & enterprise. Powered by AI, we have the highest removal rate in the industry

Medtech Syndicate Nominee

Investment focus

Medical, Health Care, Medical Device
Seed, Series A, Funding Round
Ireland

Portfolio highlights

Kite Medical — Kite medical has developed a novel device for detecting Kidney Reflux in children with Urinary Tract Infections. The non-invasive diagnostic solution for kidney reflux removes the need for complicated procedures and a hospital visit. Kidney reflux is the most common urological disorder in childhood, affecting up to three per cent of young children.It is most prevalent from six months to five years of age. The condition may resolve as the child gets older, but left undiagnosed and untreated it can lead to permanent kidney damage and ultimately to kidney failure.
Signum Surgical — Founded in 2014 by Eoin Bambury and Moshe Zilversmit, Signum Surgical is a medtech platform striving to develop technology that could cure perianal fistula. Bambury and Zilversmit, who met on the BioInnovate Ireland programme at NUI Galway, recognised a lack of innovation surrounding the treatment of perianal fistulas (small tunnels that developbetween the end of the bowel and the skin near the anus). The device developed by Signum Surgical is implanted post-surgery to prevent reinfection and to allow a faster healing process.

Enterprise Equity (or EEVC) is an excellent for providing capital to early stage and expanding business throughout Ireland.

Investment focus

Software, Information Technology, Medical Device
Funding Round, Seed, Series B
Ireland, United States, United Kingdom

Portfolio highlights

Phorest — Join 8000+ spas, barbers, hair, beauty and nail salon owners using the #1 management, scheduling, POS and appointment booking system. Try Phorest now!
SurgaColl — SurgaColl Technologies is a medical device company developing novel tissue regeneration products for the surgical treatment of diseases of the bone, cartilage and other human tissue. Based on technology developed at the Tissue Engineering Research Group (TERG) of the Royal College of Surgeons in Ireland (RCSI), headed by Professor Fergal O’Brien,the company aims to become a leader in the field of regenerative medical devices.
Metabolomic Diagnostics — Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy.

Oyster Capital Partners, an Irish private equity firm, specializes in the energy technology, IT, and healthcare sectors.

Investment focus

Software, Medical Device, Enterprise Software
Series A, Funding Round, Seed
Ireland, United Kingdom, United States

Portfolio highlights

Inclusio — The inclusio diversity and inclusion platform is designed to measure and positively shift the culture of your organisation. Contact us for more information.
Ooodles — The service platform to get premium tech products for you, your business and your employees
&Open — For businesses that gift to give back, share joy, or show they care. All you need is an email.

EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives.

Investment focus

Health Care, Medical Device, Medical
Grant, Pre-Seed, Seed
United Kingdom, Spain, Ireland

Portfolio highlights

Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
Trak — Do you know TRAK's tele rehabilitation software? Get more clinical performance and grow your physical therapy business, request a trial!
Nanordica Medical — Nanordica Medical develops novel nanoparticle-based antibacterial wound care products.

Life Sciences Fund Amsterdam is an independent venture capital fund aiming to capitalize on new technological developments in the life sciences sector. It provides investment capital to fund high tech entrepreneurial activity in the Amsterdam Metropolitan Area in general and at the academic medical centres in particular. The fund is a specialistt fund, targeting companies that are developing commercially promising products and technologies in life sciences, including: pharmaceuticals, biotechnology, medical devices and other high technology opportunities that offer venture capital returns. The Fund focuses on seed and early stage companies, but also on pre-seed commercially viable academic projects.The close collaboration between the fund, the technology transfer offices of the Life Sciences Centre Amsterdam and the Amsterdam Biomed Cluster, enables the fund to facilitate the transfer of technology to the private sector and to provide emerging technology companies and university researchers with vital seed funding and specialized financial and technical assistance. The fund started in 2007 and is now fully invested.

Investment focus

Medical Device, Medical, Communities
Series A, Funding Round, Private Equity
Ireland, The Netherlands

Portfolio highlights

Sigmascreening — At Sigmascreening, an Amsterdam based medical device company, they focus on the development of new products in the area of breast cancer screening. Sigmascreening is established as a spin-off company from the Academic Medical Center Amsterdam (AMC Amsterdam). They have several products under development, which are all aimed at improving digitalmammography, the â€œgolden standardâ€ in breast cancer screening.
Neurent Medical — Neurent Medical is dedicated to developing highly innovative non-surgical interventions that treat chronic inflammatory Sino-Nasal diseases.

Discover start-up investing made simple. Access VC-led rounds, build your portfolio, and unlock growth at Ascentifi

Investment focus

Medical, Health Care, Medical Device
Funding Round, Series A
Ireland

Portfolio highlights

Vertigenius — Vertigenius designs and deploys customized exercises using an easy-to-use clinician portal and even uses a Vertigenius head sensor to consult and manage patients with dizziness and imbalance.
Bluedrop Medical — Evidence shows regular inspection of the feet can greatly reduce the risk of developing a diabetic foot ulcer (DFU).
X-BOLT Orthapaedics — X-Bolt Trauma Solutions for osteoporotic bone fixation. FDA 510(k) approved. Clinical studies include the WHITE One (n=100) and WHITE Four (n=1,140) randomized control trials.

Glanzmann Enterprises

Investment focus

Medical, Health Care, Medical Device
Series A, Funding Round
Ireland

Portfolio highlights

Signum Surgical — Founded in 2014 by Eoin Bambury and Moshe Zilversmit, Signum Surgical is a medtech platform striving to develop technology that could cure perianal fistula. Bambury and Zilversmit, who met on the BioInnovate Ireland programme at NUI Galway, recognised a lack of innovation surrounding the treatment of perianal fistulas (small tunnels that developbetween the end of the bowel and the skin near the anus). The device developed by Signum Surgical is implanted post-surgery to prevent reinfection and to allow a faster healing process.

Early stage VC investments and funding for start-ups / founders in Ireland.

Investment focus

Software, Information Technology, Health Care
Funding Round, Seed, Series A
Ireland, United States, United Kingdom

Portfolio highlights

Jamango — Create and play for free in Jamango! Play with our block-based tools to make anything or explore a library of games and worlds instantly. No downloads.
inspeq ai — Inspeq AI uses metric-based evaluation and improves model performance, helps detect responses with low factual accuracy, and prevents them before serving to the end-users.
MarketSizer — MarketSizer offers subscription-based competitive intelligence and market insights for SaaS vendors who want to strategically grow their business.

Cantor Fitzgerald is a global financial services firm that specializes in equities, investment banking, and real estate, fixed income and currencies, prime services, and, affiliates. The firm is known for developing advanced technologies to expand market access, and help clients achieve their most important financial and strategic objectives. Thiscommitment to client-centered innovation has led to enduring relationships with many of the world’s most demanding institutional investors and corporations. The company was founded in 1945 and is headquartered in New York.

Investment focus

Biotechnology, Health Care, Medical
Post-IPO Equity, Series B, Series A
United States, Canada, Ireland

Portfolio highlights

Wejo — We unlock limitless possibilities with connected vehicle data
View — View is the leader in smart building technologies that transform buildings to improve human health and experience, reduce energy consumption and carbon emissions, and generate additional revenue for building owners. View Smart Windows use artificial intelligence to automatically adjust in response to the sun, increasing access to natural light andunobstructed views while eliminating the need for blinds and minimizing heat and glare. Every View installation includes a cloud-connected smart building platform that can be extended to reimagine the occupant experience. View is installed and designed into over 90 million square feet of buildings, including offices, hospitals, airports, educational facilities, hotels, and multifamily residences. For more information, please visit: www.view.com.
REIGO Investments — Reigo Investments is a technology company reshaping the real estate investment space. Focusing on the senior hard money lending US market, the company employs data science to improve performance, reduce defaults, and reduce underwriting time dramatically.

We work with leading corporations, startups, universities, and growers to solve the biggest challenges facing the agtech and foodtech industries.

Investment focus

AgTech, Agriculture, Farming
Pre-Seed, Seed, Funding Round
United States, Canada, Ireland

Portfolio highlights

scoutlabs — We're building the world's densest digital trap network to accurately gauge insect pest pressure. This helps millions of farmers in precisely combating crop-eating insects, accelerating a transition to more sustainable methods. Good for the farmer, the environment and for our food security
Cynomys — Soluzioni IOT di monitoraggio ambientale per allevamenti e aziende
Verdi Expeditions — Verdi is building the world's first truly scalable platform for farm automation. We work with the world's largest food brands to grow better and more sustainable crops.

We work with leading corporations, startups, universities, and growers to solve the biggest challenges facing the agtech and foodtech industries.

Investment focus

AgTech, Agriculture, Farming
Pre-Seed, Seed, Funding Round
United States, Canada, Ireland

Portfolio highlights

FarmWise — FarmWise provides technology-based services that allow farmers to streamline farm operations and increase food production efficiency.
Napigen — We are the genome editing company specialized for mitochondrial engineering. We address unmet needs of future food supplies by creating hybrid crop plants to boost their yields to an unprecedented level. The company’s technology creates robust male sterile lines that are ideal over conventional lines because of their stability and elitebackgrounds. This allows the production of non-GM hybrid seeds in crop plants that are currently mostly non-hybrid such as wheat. Our technology solution is expected to fulfill the highest level of public acceptance and aspiration.
Iamus Technologies — Iamus Technologies Limited is an Artificial Intelligence & Robotics company based in Ireland that has developed poultry specific robotic technology that empowers poultry farmers to make better and safer production decisions. Over the last 2 years we have been working globally with poultry processors in identifying KPIs that our robots cancontinuously gather on the ground in poultry sheds and feedback instantly to both producer and the relevant personnel back at the processing plant. Results to date are impressive with automatic and accurate data recovery from the birds on every part of the floor and analysis with real-time intervention now possible. These factors are key in addressing the growing demands of modern, intensive broiler production with the Iamus robot & platform meeting these requirements.

Partisan Management Group is a highly successful, early stage venture capital investor in medical device companies.

Investment focus

Medical, Health Care, Biotechnology
Funding Round, Series A, Series B
United States, Ireland

Portfolio highlights

TriSalus Life Sciences — Surefire Medical, based in Westminster, Colorado, was founded in 2009 to develop a novel infusion system for the interventional radiology market. The Surefire's Infusion System is designed to precisely deliver embolic agents through the sophisticated expandable tip portion of its catheter. Because of this differentiated expandable tip, whichcollapses in forwarding flow to maintain blood flow and dynamically expands to the vessel wall in reverse flow to minimize reflux, Surefire's Infusion System is designed to substantially reduce damage to healthy tissue.
Enable Injections — Enable Injections designs, manufactures, and sells wearable delivery devices for injectable drugs. The Enable Injections products can deliver drugs directly from standard vials supplied by all pharmaceutical companies, can reconstitute powdered drugs into liquids as a part of the injection procedure, can inject very viscous drugs, and can inject upto 20 ml. Such products are called bolus injection systems. No other existing drug delivery device can accomplish all of these tasks. Approximately 900 new drugs are being developed that may require bolus injection technology like that being developed by Enable Injections. The total market is expected to reach $8 billion within ten years. Partisan principals have supplied 10% of the seed capital to Enable Injections. It also delivers a controlled flow of up to 50 ml of a biologic through an automatically inserted needle. Enable Injections also offers a version of the drug delivery platform that may connect to smartphones via Bluetooth. It also utilizes any standard container closure system, including syringes or vials; automatically warms and can automatically mix lyophilized solutions.Enable Injections was founded in 2010 and is headquartered in Cincinnati, Ohio, USA.
Ponce De Leon Pharmaceuticals — Ponce De Leon Pharmaceuticals is a privately financed development stage company, committed to the extension of human health span, endeavoring to offer more healthy years of living. In conjunction with the Buck Institute for Research on Aging, the Company has developed a formulation comprised of GRAS (Generally Regarded As Safe) components. Thisformulation has been shown to radically increase mean lifespan in the invertebrate model (C. Elegan), well beyond any previously published data on drugs or compounds. Testing has now begun at the Buck Institute in the mammalian model (mouse), and the Company hopes to have a patent pending product available to the public at the conclusion of those studies, or in about three years.

Boole

Investment focus

Medical Device, Health Care, Medical
Seed, Funding Round
Ireland

Portfolio highlights

Incereb — Lifelines Neuro offers exceptional infant EEG electrodes with Incereb. Learn more about this wonderful device for neonates in the NICU.
ProVerum Medical — ProVerum Medical is an early stage medical device startup for the treatment of Benign Prostatic Hyperplasia (BPH).

New Leaf Venture Partners is a venture capital firm funding the healthcare revolution by investing exclusively in companies revolutionizing healthcare.

Investment focus

Health Care, Biotechnology, Medical
Series B, Series C, Series A
United States, United Kingdom, Canada

Portfolio highlights

Qlaris Bio — Qlaris Bio focuses on developing novel and innovative therapies for serious and debilitating ophthalmic diseases. Qlaris Bio is a spinout company of Qrativ, a biotechnology incubator formed as a joint venture between Mayo Clinic and inference, a pharmaceutical-focused artificial intelligence company. Its lead program is QLS-101, a novel compoundinvented at Mayo Clinic and the University of Minnesota. QLS-101, with its unique and first-in-class mechanism of action, may potentially serve as an efficacious treatment for high unmet need conditions related to disturbances in intraocular pressure, including a sight-threatening and progressive Pediatric Rare Disease for which effective therapies remain elusive and limited.Qlaris Bio was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Flosonics — Flosonics Medical is improving patient care through technology-enabled solutions and services that clinicians, and patients, love.
Harpoon Therapeutics — Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, orantigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

Malin Corporation plc (“Malin”) is an Irish incorporated public limited company whose head office is in Dublin, Ireland with subsidiary offices in New Haven, Connecticut and Research Triangle, North Carolina, USA.Malin’s purpose is to create shareholder value through the selective long-term application of capital and operational expertise toprivate, pre-IPO, pre-trade sale operating businesses in dynamic and fast growing segments of the life sciences industry. Through its operational involvement, Malin works with its investee companies to enable them to reach the full potential of their value proposition and to achieve commercial success.

Investment focus

Biotechnology, Health Care, Biopharma
Funding Round, Series B, Series C
United States, United Kingdom, Ireland

Portfolio highlights

CG Oncology — CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder saving therapeutics for patients with bladder cancer.
Poseida Therapeutics — Poseida Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies with the capacity to cure cancers and genetic diseases.
Xenex — Xenex is offering an effective approach to reducing the incidence of healthcare-associated infections.The Xenex mission is to save lives and reduce suffering by destroying deadly microorganisms that can cause hospital-acquired infections (HAIs). Xenex’s Pulsed Xenon Full Spectrum™ UV Disinfection Solution reduces the bacterial load oftenassociated with an increased risk for HAIs. Since its commercial launch in June 2010, Xenex devices are now included in infection control protocols in almost three hundred hospitals throughout the U.S.Xenex was founded in 2009 and headquartered in San Antonio, Texas.

Norgine Ventures was started in 2012 to diversify Norgine’s activities and foster innovation in the healthcare sector. Norgine Ventures provides debt and debt-like financing to innovative, fast-growing companies in the fields of healthcare and life sciences, in Europe and the US. Norgine Ventures is backed by Norgine, a fully integrated, private,European healthcare company with over 110 years of experience in the pharma space.Norgine Ventures has full access to Norgine’s technical capabilities for evaluating investment opportunities, although the business is aimed at achieving a financial return rather than funding opportunities of strategic interest to Norgine.To date, Norgine Ventures has invested in a number of businesses, including specialty pharma, diagnostic and medical device companies, at various stages of their life cycle, both in Europe and in the US.

Investment focus

Health Care, Medical Device, Biotechnology
Funding Round, Debt Financing, Series A
France, United Kingdom, United States

Portfolio highlights

ImaginAb — ImaginAb is a biotechnology company focused on developing a new class of highly targeted diagnostic imaging agents based on engineered antibody fragments. ImaginAb's platform technology enables the rapid engineering of antibodies into fragments that retain the parental antibody but are immunologically passive and kinetically-optimized forclinical imaging. This combination of superior specificity and kinetics enables ImaginAb to generate agents that can address the unmet needs in diagnosis and patient selection for therapeutics.
PathoQuest — PathoQuest provides biosafety assays based on next-generation sequencing (NGS) for biologics quality testing. GMP biotesting for biopharmaceuticals. Learn more.
Impress — Impress – is European leading digital orthodontic DSO of new generationWe have a defensible model with the personal touch of an in-house orthodontist, true clinical expertise, and engaging directly with consumersImpress was founded in 2019 in Barcelona with the idea of combining the best of orthodontic tradition with the most innovativetechnology in the sector. From the very beginning the vision of the Impress founders was to introduce a different business model with a strong focus on medical experience and digitalization. The company is transforming the oral healthcare industry by developing its own chain of orthodontic clinics, which are characterized by their disruptive design and modern patient experience. The founders decided to build a medical company with the personal touch of in-house orthodontists, face-to-face care, and unique clinical expertise, where the proper implementation of business processes and digitalization are at the core.In less than 2 years, Impress has managed to position itself as the European leader in the orthodontic sector, has treated more than 22.000 smiles and already has a presence in more than 80 European cities. Its innovation and quality have earned it recognition from Sifted as one of the fastest growing HealthTech companies in Europe in 2020.

Founded in 1997, Earlybird invests in all development and growth phases of technology companies. Among the most experienced venture investors in Europe, Earlybird offers its portfolio companies not only financial resources but also strategic support plus access to an international network and capital markets. With EUR 2 billion under management,eight IPOs and 30 trade sales, Earlybird is one of the most established and active venture capital firms in Europe.

Investment focus

Software, Information Technology, Health Care
Series A, Seed, Series B
Germany, United States, United Kingdom

Portfolio highlights

Proofs — The go-to-market for software. AI Agents building proof-of-concept apps and integrations on top of APIs
M^0 Labs — M^0 is money middleware for the digital age. It is a decentralized, on-chain protocol, as well as a corresponding set of off-chain standards and APIs, that allows holders of high-quality eligible collateral to participate in the issuance of a fungible cryptodollar. With M^0, any number of institutions around the world can tap on turnkey middlewareto become their own cryptodollar issuer, upgrading their money tech stack to the digital age.
Zeta Labs — Revolutionize daily tasks with our AI assistant. Not just a chatbot - it chats, understands, and performs. Free yourself to focus on meaningful things.

European Investment Bank (EIB) provides lending, borrowing, and treasury services primarily in the European Union.The company offers project loans for the public and private sectors; loans to banks and other intermediaries; structured finance products; guarantees and securitization instruments for senior and subordinated debts; project bonds;equity and fund investment products such as infrastructure equity and debt funds, and environmental funds; and venture capital funds and security packages for funds.The company also offers microfinance; risk sharing finance for research, development, and innovation projects; finance and technical expertise for sustainable energy projects; infrastructure project advisory services; support for urban development projects; guarantees for transport infrastructure; and funding for public-private partnerships and small- and medium-sized enterprises.EIB serves the transportation, global loans, energy, industry, health, education, water, sewerage, infrastructure, services, telecommunications, agriculture, and fisheries sectors.European Investment Bank was founded in 1958 and is based in Luxembourg.

Investment focus

Biotechnology, Health Care, Software
Debt Financing, Post-IPO Debt, Funding Round
France, Germany, The Netherlands

Portfolio highlights

Rohlik — Rohlik is an innovative grocery delivery startup that offers a 90-minute same-day delivery service. Since its inception, Rohlik has been growing and is on track to EUR 300 mil. revenues in 2020. Rohlík was founded in 2014 by Marek Sacha and Tomas Cupr and is headquartered in Karlín, Hlavni mesto Praha, Czech Republic.
Eldrive — The largest charging point operator in Eastern Europe | Our network is expanding rapidly yet our focus is fixed on renewables, for a greener future. We provide AC & DC charging across Bulgaria, Romania and Lithuania.
ABN AMRO Bank — Als bank leggen wij de focus op inclusiviteit, duurzaamheid, sociaal ondernemen, innovatie, dagelijkse bankzaken en meer.

The Manatt Venture Fund is the investment arm of Manatt, Phelps & Phillips, LLP, a Los Angeles-based law firm. The Fund makes early-stage investments, and since its founding in 2000 it has made investments in over 90 companies. The official investment entity is MPP Holdings, LLC.

Investment focus

Mobile, Software, Internet
Series A, Seed, Series B
United States, Canada, Ireland

Portfolio highlights

Percent — Unlock private credit investments with Percent. Access alternative investments on the platform powering the future of private markets.
Motion — Motion is a visual analysis hub that helps marketers and creative teams identify what works to make high-performing creatives that convert.
Genome Medical — We are genetic experts who partner with healthcare organizations to deliver best-in-class genetic counseling services and bring precision medicine to more lives.

Crow Rock Capital is an investment firm.

Investment focus

Medical, Health Care, Medical Device
Funding Round
Ireland

Portfolio highlights

HealthBeacon — The World's Leading Digital Health Platform for Injectable Medications As many as 1-in-2 patients fail to adhere to their medication schedule. Our

Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series B, Series A, Series C
United States, France, Switzerland

Portfolio highlights

Avenzo Therapeutics — Developing the next generation of oncology therapies for patients.
Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
Aeovian Pharmaceuticals — Aeovian is a San Francisco based biopharmaceutical company developing novel and highly selective therapeutics modulating mTORC1 pathway.

Medicxi is a life sciences-focused investment firm, originally created at Index Ventures, a leading international venture capital firm with offices in London, San Francisco, Geneva, and St. Helier (Jersey).Francesco De Rubertis joined Index at the end of 1997 to launch the firm's life sciences practice and was joined in the following yearsby three partners: Kevin Johnson, Michèle Ollier and David Grainger. Over the years, Index raised a total of twelve funds, managed with separate life sciences and technology investment teams.In 2012, Index launched sector-specific venture funds for the first time, raising separately Index Ventures VI (technology focus) and Index Life VI (life sciences focus). Global Pharma GlaxoSmithKline (NYSE: GSK) and affiliates of Johnson & Johnson (Janssen; NYSE: JNJ) both partnered with Index by investing in Index Life VI. This was a key step in the path towards the founding of Medicxi as an independent venture firm. (read here)Medicxi started its operations in February 2016, with offices in London, Geneva and St Helier (Jersey). Giuseppe Zocco, co-founder of Index Ventures, joined Medicxi shortly thereafter to help build the firm’s late-stage platform and lead the launch of its first Medicxi Growth fund, MG1. (read here)Currently, the firm is actively investing its 2 most recent funds, Medicxi Ventures 1 (focus on early-stage companies) and Medicxi Growth 1 (focus on later stage companies), in addition to managing the entire portfolio of all prior Index life sciences investments.The firm is led by its five co-founders and Partners: Francesco, Kevin, Michèle, David and Giuseppe. Over the years, the five of them have collectively been involved in starting over seventy companies in several countries.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, United Kingdom, The Netherlands

Portfolio highlights

D3 Bio — D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, our new medicine development approach is fundamentally differentiated. We do not just only start with science in the lab. First, we pinpoint the greatest unmet patient and market needs – whereexisting standard-of-care approaches yield unsatisfactory clinical outcomes. Then we take those insights into the lab to guide the identification of fit for purpose science and technology and define our drug development path.
ProfoundBio — ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
Alys Pharmaceuticals — Alys Pharmaceuticals engages in immuno-dermatology services. The company is reshaping the treatment landscape through advanced scientific innovations and a strong research and development-focused multi-platform pipeline. Alys emerged as a result of the strategic aggregation of 6 asset-centric companies backed by Medicxi.

Apicap offers investment and co-investment solutions for managers, wealthy private clients and institutional investors.

Investment focus

Software, Information Technology, Mobile
Funding Round, Series A, Series B
France, United States, Turkey

Portfolio highlights

Crowdaa — Crowdaa is a mobile-only music store where producers decide how to distribute and monetise their content.
Feelbat — FEELBAT offers technical solutions for remote crack monitoring, covering installation and data analysis to assist in wall monitoring.
Karma Koma — Karma Koma is specializes in retail and French and international distribution with multi-brand resellers.

HBM-MedFocus

Investment focus

Health Care, Biotechnology, Medical Device
Series A, Series B
Ireland, United States

Portfolio highlights

Perfuze — Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative cathetertechnology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.
Viseon — Viseon is a privately held medical device company committed to developing proprietary technology for use in Minimally Invasive Spine Surgery (MISS) procedures. Viseon has progressed rapidly over the past 6-months, having developed a unique array of devices to improve the procedural and clinical outcomes of many minimally invasive spine surgeryprocedures. In addition to rapid product development of its initial products, Viseon has assembled a world-class Scientific Advisory Board of leading MISS physicians, amassed 13 patents to solidify its intellectual property platform, and completed a series of pre-clinical studies supporting initial human-use, scheduled to begin soon.Viseon was founded in early 2017 as a spin-out from Rebound Therapeutics Corporation.

Moffett Investment Holdings is an investment firm

Investment focus

Medical, Health Care, Biotechnology
Series A, Series B
Ireland

Portfolio highlights

Neuromod Devices — Neuromod is a medical device company formed to advance the science of bi-modal neuromodulation.We are committed to delivering treatments that significantly reduce the suffering of underserved patient populations who live with chronic and debilitating conditions globally. Our goal is to design products that empower patients to take control oftheir own treatment, delivering targeted therapies that integrate seamlessly into a modern lifestyle.Neuromod has developed and patented a bi-modal neuromodulation technology that it is evaluating for neurological disorders including chronic tinnitus, a condition affecting 10% of the adult population and commonly known as 'ringing in the ears'.

Frazier Healthcare Partners: Investing exclusively in healthcare for 25 years.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Post-IPO Equity
United States, Canada, Ireland

Portfolio highlights

Metagenomi — Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems.
Pardes Biosciences — Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines.The company’s lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences is on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.
New Amsterdam Pharma — NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.

DHKN has professionals in Audit, Accountancy, Corporate Finance, Tax Consultancy & Compliance, Outsourced Services and Corporate Governance & Compliance firm all under one roof in Galway.

Investment focus

Medical, Health Care, Medical Device
Funding Round
Ireland

Portfolio highlights

Versono Medical — Versono Medical is an early stage Irish MedTech company located in Galway. Our focus is on a new Medical Technology for Endovascular Surgery.

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Funding Round
United States, Sweden, France

Portfolio highlights

ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Vicore Pharma — Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
Rampart Bioscience — Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases. It also offers proprietary development and delivery platforms, which together, create optimized therapeutics in a revocable, non-viral format. It also assists patients with genetically driven diseases by integrating capabilities from avariety of key scientific disciplines including gene delivery, protein sciences, and clinical translation.

Keiretsu Forum is a community of private equity investors, business leaders and entrepreneurs with a network of over 50 global chapters and more than 2,500 investor members.

Investment focus

Health Care, Software, Biotechnology
Series A, Seed, Funding Round
United States, Spain, Canada

Portfolio highlights

iQure Pharma — iQure Pharma preclinical and clinical drug development
Levered Learning — Levered Learning is a classroom-tested and teacher-designed instructional system providing 3rd-5th grade mathematical learning. The company was founded in 2017 by Mitch Slater and is headquartered in Soquel, California, United States.
Vartega — Vartega is a technology development company specializing in the carbon fiber-reinforced plastic recycling process. We have developed alternative technology, processes, and equipment to provide low-cost carbon fiber for use in mass market applications.

Kreos Capital is Europe's largest and leading provider of growth debt to high-growth companies with revenues up to €150 million. Since 1998, as the pioneer growth debt provider across the UK, Western Europe, Scandinavia and Israel: Kreos has completed nearly 450 transactions and committed €1.8 billion in 14 different countries. Kreos has aproven track record of adding value to portfolio companies and helping them to grow with additional capital and flexibility throughout their business cycle whilst working closely with both the portfolio company management team and their equity sponsors.The Kreos global team has extensive debt financing, management and equity investing experience, covering the pan-European market from its locations in London, Tel Aviv and Stockholm.Kreos is a value added partner, able to offer additional capital and more flexibility with lower equity dilution. Kreos's international team has extensive entrepreneurial, debt financing and equity investing experience, covering all local European markets from its locations in London, Tel Aviv and Stockholm.

Investment focus

Biotechnology, Health Care, Software
Debt Financing, Series B, Post-IPO Debt
United Kingdom, Germany, United States

Portfolio highlights

Abivax — Abivax recently presented impressive 9-month interim extension data from studies of ABX464 in ulcerative colitis during an oral presentation at DDW 2019, demonstrating a continued duration of beneficial effect in patients after 11-months of treatment. View the conference presentation, here:
BiolineRx — BioLineRx is building a best-in-class pipeline designed to deliver meaningful therapeutic benefit to patients with certain cancers and rare diseases.
Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

EarlyBird is a postal snacking service that delivers healthy snacks to its users’ doorstep. It provides its users with TasteBox, 5 healthy snacks and 2 unique teas, to help them through the working week. Its TasteBox also contains music and art from up and coming artists. EarlyBird was launched in 2014 and is based in London, England.

Investment focus

Financial Services, FinTech, Health Care
Seed, Series A, Pre-Seed
Germany, Ireland, Romania

Portfolio highlights

Sikoia — Streamline your decision-making with centralized customer data, comprehensive case management, and automated risk evaluation without complicated integrations.
Noscendo — Noscendo operates as a diagnostics company dedicated to the identification and assessment of bloodstream-associated pathogens and other infections.
Goodlegal — Goodlegal is the One-Stop-Shop for all your Legal needs. Get an out-of-the-box Legal Infrastructure Platform to handle all your problems.

Foresight Group is a listed infrastructure and private equity investment manager which has been managing funds on behalf of institutions and retail clients for more than 35 years. Foresight has over £7.2 billion of assets under management across a number of funds on behalf of some of the world’s largest institutional investors, family offices,private and high net-worth individuals and retail investors. Foresight's investment strategies are underpinned by a strong environmental, social & governance (“ESG”) focus, which increasingly meets the demands of today’s investors and ensures we are consistently working towards creating a sustainable legacy for future generations.

Investment focus

Software, Manufacturing, Health Care
Funding Round, Private Equity, Seed
United Kingdom, United States, Jersey

Portfolio highlights

Workbuzz — Issue employee engagement surveys with WorkBuzz - a fast, simple, and flexible platform with expert consultancy. Try it now!
We Are Fulfilment — We Are Fulfillment is an e-commerce company that provides warehousing and management services.
MSL Property Care Services — MSL Property Care Services provides property maintenance services.

Inventages Venture Capital Investment Inc is an investment arm of Nestle SA specializing in PIPES, seed, early, mid, and late venture investments. The firm seeks to invest in middle market and mature companies. It provides mezzanine and bridge financing. The firm seeks to invest in health care, life sciences, cosmeceuticals, pharmaceuticals,enabling technologies and services, and diagnostic and medical devices. Within the pharmaceutical sector, it typically invests in small molecules, proteins, antibodies, vaccines, phytopharmaceuticals, natural compounds, botanicals, antibiotics, and therapeutics. Within the diagnostic sector, it focuses on genetic materials, biomarkers, pathological markers, genetic profiles, protein profiles, pharmacogenomics, food and environmental safety, genetically modified organism detection and trading, medical monitoring, diagnostic and analytical tools, and quality control. Within enabling technologies and services it primarily invests in novel packaging, process and production technologies, supply chain management, innovative materials and resources, delivery systems for active compounds, encapsulation and prevention, food services, extraction and fractionation of biological materials, consumer relation management, green biotechnology, smell and taste modifying technologies, genomics, proteomics, metabolomics, screen and characterization technologies, chemical and biological engineering, and innovative preventive and therapeutic concepts. It also invests in companies involved in the prevention of medical foods, nutraceuticals, cosmoceuticals, nutrition, innovative food, functional food, dietary and food supplements, oral and skin care, immune modulation and stimulation, and health and disease management.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Funding Round
United States, United Kingdom, Canada

Portfolio highlights

Accera — Accera is a biotechnology company that engages in the discovery and development of therapeutic drugs for neurodegenerative diseases. It offers Ketasyn, a molecule for Alzheimer's, Parkinson's, and age-associated memory impairment. It was founded in 2001 and is headquartered in Broomfield, Colorado.
XOLUTION — XOLUTION is the most advanced reclosable beverage container solution. Already in its prototype state, the new XO resealable can won the Can of the Year Award in Dubai in 2009 (Winner Silver - Category Prototype) and was enhanced and refined since, involving extensive market research and field testing. With the can now entering the consumer beveragemarket, they are confident that the product resembles a step forward for XOLUTION in becoming the market leader in this field. XOLUTION GmbH is headquartered in Munich, Germany. In 2008, Marc von Rettberg was named Chief Executive of the company. He joined Christian Bratsch, Vice President R&D, to introduce innovative designs to the beverage packaging industry for reclosable beverage cans.Rettberg and Bratsch established new product design guidelines with a clear focus on values and benefits for the entire supply chain. The innovative beverage can ends were required to offer easy usage to the consumer (intuitive, easy to open and reseal), easy integration for the beverage filler in the existing processes (no major adjustments to the filling line), easy handling for the can maker (XO reclosable can ends based on standard shells), and improved commercialization for the beverage brand (unique branding options). And, of course, the focus was set on providing these benefits at a reasonable overall cost.In 2009, Can Maker Magazine recognized the XOLUTION innovative resealable can with the Silver Award in the Prototype category for the XO-400 reclosable beverage can lid. Since Time-to-Market is a key challenge for all innovators, Rettberg and Bratsch have created a competitive advantage of rapid prototyping and testing capabilities in their Salzburg R&D Center. XOLUTION GmbH is managed by one of the most competent teams in the business. With long-term experiences in their respective fields, their leading specialists guarantee the best coverage of all business areas from prototyping, R&D and product management to trading and distribution. With their knowledge, the XO Resealable Can was successfully converted from a simple vision to a technologically sophisticated product that will have a significant influence on the canned beverage market.
Ripple Foods — Ripple Foods specializes in making non-dairy milk with just as much protein as milk and half the sugar. Ripple has 8x the protein of almond milk and half the sugar of dairy milk. It’s high in bioavailable calcium (50% more than milk), potassium and provides a good source of omega-3s. It’s lower in calories than milk and best of all, it has thecreamy, delicious texture our dairy-free friends are missing. No more thin, chalky almond/ soy/ cashew milk.It was founded in 2014 and headquartered in Emeryville, California.

Silicon Valley Bank is the financial partner of the innovation economy; helping individuals and investors in the innovation ecosystem achieve extraordinary outcomes.

Investment focus

Software, Health Care, Biotechnology
Debt Financing, Series B, Series A
United States, United Kingdom, Canada

Portfolio highlights

Denim — Denim is an all-in-one financial enablement platform for the logistics industry. We work with brokerages to offer freight factoring and back office automation.
Harness — Harness is a self-service CI/CD platform that allows engineers and DevOps to build, test, deploy, and verify software, on-demand.
Parafin — Parafin provides you with an end-to-end solution to offer one-click financing to your sellers.

Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.

Investment focus

Software, Biotechnology, Health Care
Series A, Series B, Series C
United States, United Kingdom, Israel

Portfolio highlights

Aim Security — Aim is the industry guide to secure GenAI adoption, empowering security leaders to drive business productivity while ensuring proactive protection for all GenAI use cases.
Reibus — Reibus is the leading platform for buying and selling steel and other metals, with end-to-end services including logistics and financing.
Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the antigen repertoire in cancer.